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Abstract: The most robust and frequently reported cognitive deficits in type 2 diabetes (DM2) are those that relate to 
memory. Behavioural research has identified a number of potential contributory physiological factors, including abnor-
malities in glucose metabolism, such as hyperglycaemia and hypoglycaemia. The impact of these mechanisms on memory 
has been further investigated through the use of both structural and functional neuroimaging. Structural brain imaging has 
indicated that memory impairments in DM2 are associated with global atrophy of the brain. Further data suggest that lo-
calised atrophy in the hippocampal area, a brain region critical to memory formation and consolidation, may be primarily 
responsible for the memory deficits seen in this population. Functional imaging data has corroborates these findings, with 
functional magnetic resonance imaging (fMRI) suggesting reduced connectivity between the hippocampus and surround-
ing brain regions, particularly the frontal and temporal gyri. Despite this, little functional neuroimaging research has di-
rectly investigated differences in regional brain activity between healthy and DM2 participants whilst memory tasks are 
being performed. By using neuroimaging techniques to their full potential, we can acquire a fuller, more comprehensive 
picture of the impact that DM2 has on memory. 
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Type 2 diabetes (DM2) in older adults is associated with 
cognitive impairment, reflecting accelerated cognitive de-
cline relative to that expected in normal ageing [1-3]. The 
most frequently reported and most robust deficits are seen in 
verbal episodic memory [4], although other domains of 
memory such as face recognition and working memory may 
also be affected [5, 6]. However, it is still unclear whether 
these deficits reflect impairments in their encoding or re-
trieval. These memory impairments have been attributed to 
varied physiological mechanisms, including abnormalities in 
glucose metabolism, insulin resistance, dysregulation of the 
hypothalamic-pituitary-adrenal (HPA) axis and vascular 
complications [7, 8]. The role of these physiological mecha-
nisms in neurocognitive functioning in individuals withDM2 
has been investigated using a variety of neuroimaging tech-
niques. Methods such as magnetic resonance imaging (MRI) 
and electroencephalography (EEG), have allowed research-
ers to examine both the structural and functional impact of 
DM2 on the brain. This review will consider these neuroi-
maging studies and speculate on how these innovative tech-
niques could be informative in identifying underlying 
mechanisms of memory deficits in DM2. 
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DM2 AND COGNITIVE IMPAIRMENT: THE 
MECHANISMS 
Disturbances in glucose metabolism, including hypergly-
caemia and hypoglycaemia, have been associated with cog-
nitive dysfunction [7, 9]. Summerfield, Deary and Frier [7] 
observed that induced acute hyperglycaemia in adults with 
DM2 impaired cognitive performance, most notably in the 
working memory domain. Relatively few studies have inves-
tigated the effects of chronic hyperglycaemia on memory. 
High glycated haemoglobin (HbA1c) levels have been asso-
ciated with general cognitive and memory deficits in DM2 
[10, 11], but findings are mixed. The recent ACCORD-
MIND study failed to observe any benefits to working or 
verbal episodicmemory as a result of improving glycaemic 
control (20-40 month follow up) [12]. By contrast, a 24 week 
long study by Ryan et al. [5] showed that improvedglycae-
mic control led to improved working memory, although no 
improvement in verbal memory was observed. Whilst com-
parable cognitive tests were used by both Launer et al. and 
Ryan and colleagues, the shorter follow up period and 
smaller sample size (145 participants vs. over 2000 in the 
ACCORD-MIND study) of Ryan et al’s. study were poten-
tially insufficient to account for longer term effects of tighter 
glycaemic control. These findings suggest that the deficits 
caused by hyperglycaemia may be irreversible and highlight 
the importance of very early interventions to reduce the 
length of exposure to chronically high blood glucose. 
Hypoglycaemia has alsobeen shown to adversely affect 
memory. In healthy adults, induced hypoglycaemia via a  
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hyperinsulinemic glucose clamp has been found to impair 
working and delayed visual memory [13]. Aung and col-
leagues [14] reported that DM2 patients who had a self-
reported history of severe hypoglycaemia performed signifi-
cantly worse on age-sensitive neuropsychological tests (Ver-
bal Fluency, the Digit Symbol test and Letter-Number se-
quencing from the Wechsler Adult Intelligence Scale III and 
the Trail-Making Test Part B) compared to those who had no 
history of this condition. The authors derived a general late-
life cognitive ability factor from these tests (which they 
called ‘g’), and reported that hypoglycaemia was a contribut-
ing factor to cognitive decline, even after pre-morbid intelli-
gence and other confounds were statistically controlled. De-
spite its apparent detrimental effects, the occurrence of hy-
poglycaemia in DM2 is not commonly reported, possibly 
due to patients being unaware of its symptoms when mild 
hypoglycaemia occurs [15, 16]. Further long term investiga-
tion of hypoglycaemia’s effects on cognitive performance in 
DM2 is clearly needed. 
In addition to the accelerated cognitive decline observed 
in DM2, it is also reported that people with DM2 are at 
greater risk of dementia [2, 17]. This risk is most often at-
tributed to the effects of hyperglycaemia on the brain, al-
though severe episodes of hypoglycaemia may also increase 
its probability [18]. Further, a combined factor of verbal epi-
sodic memory deficits and elevated glycaemia has been 
found to predict ‘pre-dementia’, highlighting the complex 
relationship existing between diabetes, dementia and cogni-
tive function [19]. This may be a consequence of an accumu-
lation of advanced glycation end-products and oxidative 
stress, which are believed to contribute to neuronal damage 
in DM2, and are also seen in Alzheimer’s disease (AD) [20, 
21]. Considering this, research into the damaging effects of 
type 2 diabetes on brain structure and function is of critical 
importance to understanding the extent to which cognitive 
processes, including memory, are affected. 
DM2 AND THE BRAIN– GLOBAL STRUCTURE 
Despite continued research, no clear consensus has 
emerged regarding the effects that DM2 has onwhole brain 
structure. Some studies suggest that DM2 leads to increased 
loss of neurons (brain atrophy), a higher incidence of brain 
infarcts caused by blocked blood vessels in the brain, and 
white matter hyperintensities (WMHs), all resulting in poor 
cognitive performance [4, 22]. Considering this, Manschot, 
Biessels, de Valk, Algra and van der Grond et al. [4] used 
MRI (see Appendix 1) to determine the potential effects of 
abnormal glucose metabolism on the structural integrity of 
the brain and cognition. On MRI measures, patients had sig-
nificantly more infarcts and more severe brain atrophy (cor-
tical and subcortical) than controls, although no specific 
brain regions were reportedly affected. They also found that 
individuals with DM2 performed significantly worse on 
three cognitive measures (including verbal episodic memory) 
compared to healthy controls, implying hippocampal and 
temporal gyrispecific deficits. However, Christman et al. 
[23] found that there was no difference in grey matter vol-
ume, white matter volume or number of WMHs between 
healthy participants and those with DM2, although those 
with DM2 had smaller brain to intercranial volumes. This 
suggests that those with DM2 may experience higher shrink-
age of the brain compared to their healthy counterparts. 
These mixed findings may be due to the differing sample 
sizes and patient to healthy control ratios. Manschot et al. 
compared 122 DM2 participants with 56 healthy partici-
pants; whilst in Christman’s study, only 25 DM2 participants 
were compared to 150 controls. 
Whether structural integrity is affected longitudinally and 
by vascular disease is also of interest. In a three year longi-
tudinal study, van Elderen et al. [24] used MRI to investigate 
the differences in neurodegenerative progression and cogni-
tion between healthy controls and DM2 patients aged be-
tween 70-82 years old. Over the three year period, they noted 
changes in the number of infarctions, total brain volume 
changes and WMH volume changes from baseline. Patients 
showed significantly more total brain atrophy at follow-up 
compared to healthy controls, but there were no between-
group differences in WMH volume changes or number of 
infarctions. On tests of cognitive function, their DM2 par-
ticipants performed worse at baseline on all three tasks (a 
modified Stroop task and a test of delayed and immediate 
visual memory recall) than controls. At follow-up, their pa-
tients only showed significant decline on the Stroop task and 
immediate recallcompared to controls, with only visual 
memory scores correlating with total brain atrophy. Tiehuis 
and colleagues [22] investigated whether vascular disease 
and DM2 independently affected cognition andbrain struc-
ture in individuals with arterial disease. Overall, individuals 
with both DM2 and arterial disease performed worse on tests 
of attention, memory and visuoperception compared to those 
with arterial disease alone, even after adjustment for vascular 
risk factors. DM2 participants had more brain atrophy, white 
matter lesions and lacunar infarcts. Global and cortical atro-
phy were significantly negatively associated with an overall 
composite scoreof cognition (derived from the three afore-
mentioned domains and executive function test scores) in 
participants with DM2, both with and without arterial dis-
ease, suggesting that DM2 affects cognition irrespective of 
arterial disease status. In a related study, the authors also 
found that duration of illness for diabetes contributed to 
global brain atrophy in those with both DM2 and arterial 
disease [25], indicating that duration of impaired glucoregu-
lation is also a modifying factor in DM2 cognition. Both 
vanElderen and colleagues and Tiehuis et al’s. studies indi-
cate that global brain atrophy in DM2 is correlated with 
memory decline, but neither speculate how this atrophy af-
fects specific memory processes, such as the encoding, stor-
age or retrieval of memories. By not considering the influ-
ence of atrophy on precise mechanisms, they overlook neu-
rocognitive mechanisms which may underpin cognitive im-
pairment in DM2. 
The pivotal ACCORD trial’s sub-study, Memory in Dia-
betes (MIND), has suggested that intensive glycaemic ther-
apy (involving the reduction of patient HbA1c levels to less 
than 6.0%)versus standard glycaemic therapy (HbA1c levels 
targeted between 7.0-7.9%) through a range of strategies and 
drug classes does not reduce the overall effects of diabetes 
on memory [12]. Regardless, the results did indicate that 
those on the intensive therapy had higher total brain volumes 
at the end of the trial relative to those on standard therapy, 
suggesting that the rate of brain atrophy can be reduced with 
improved glycaemic control. However, in this respect none 
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of the studies above consider whether type 2 diabetes has an 
adverse effect on specific brain regionscritical to cognitiveor 
memory processing, such as thehippocampus. The location 
of where lesions and infarcts occur should be more precisely 
measured in the hippocampus to fully consider their impact. 
DM2 AND THE BRAIN – THE HIPPOCAMPUS 
Research suggests that participants with DM2 have in-
creased hippocampal atrophy compared to health controls 
[26] and that this is related tohippocampally-mediated defi-
cits in the verbal episodic memory domain(see Appendix 2 
for an explanation of the role of the hippocampus in mem-
ory) [27]. A recent study by Hayashi et al. [28] found that in 
Japanese older adults (aged over 65), DM2 participants 
showed more hippocampal and whole brain atrophy than 
healthy controls. They also found that hippocampal atrophy 
correlated negatively with cognitive function (as measured 
using the Mini-Mental State Examination and the Revised 
Hasegawa Dementia Scale). Reduced hippocampal volume 
coupled with reports of reduced connectivity to surrounding 
brain regions [29] may explain cognitive impairment in 
DM2, although the tests employed by Hayashi et al are not 
sufficiently sensitive to specific memory deficits. Another 
study by Yau et al. [30] used diffusion tensor imaging (DTI), 
a type of MRI that allows examination of water molecule 
diffusion in tissues and white matter, to investigate white 
matter abnormalities and emotional memory in DM2. They 
found that patients had impaired emotional memorycom-
pared to healthy controls. The DTI results revealed signifi-
cant white matter abnormalities in DM2 patients, particularly 
in areas involved in memory and emotion processing (right 
prefrontal and, left middle and left superior temporal corti-
ces). Although the above studies attempted to couple struc-
tural abnormalities in memory-related brain regions with 
behavioural evidence, they did not analyse the functional 
integrity of these regions. 
Interestingly, it has been further suggested that there is 
evidence of sex differences in DM2 hippocampal volume 
reductions. In the general population, women are found to 
have larger hippocampi than men [31]. In a study investigat-
ing sex effects on hippocampal volume in DM2, Hempel and 
colleagues [32] found that women had more substantial vol-
ume reductions relative to healthy controls than those ob-
served in men. The authors suggested that women with DM2 
may therefore suffer more brain complications relative to 
their male counterparts, despite having better glucose control 
on average [32]. Yau et al. [30] found that there was a trend 
toward blunted emotional memory facilitation in female dia-
betic participants but not in males. Therefore, there is robust 
evidence of an association between hippocampal integrity 
and cognitive performance in DM2. As the hippocampus 
appears to be the brain region which is preferentially affected 
in DM2 [27], the extent of the impact that hippocampal atro-
phy may have on functional capacity of this brain region, 
particularly for memory, may be further investigated using 
functional neuroimaging. 
DM2 AND FUNCTIONAL BRAIN IMAGING 
The majority of neuroimaging studies have sought to de-
termine which structural abnormalities are associated with 
the cognitive decline observed in DM2. Very few studies to 
date have employed MRI to uncover the functional bases of 
memory impairments in DM2 (see Appendix 3). Zhou et al. 
[29] asked DM2 patients and healthy controls to complete a 
variety of cognitive tests, with the aim of comparing cogni-
tive performance to the resting-state functional connectivity 
(where the BOLD response is monitored in the absence of 
the participant performing an explicit task) of the hippocam-
pus. They found that DM2 participants’ performance was 
significantly worse on a number of neuropsychological tests, 
including the Auditory Verbal Learning Test of verbal epi-
sodic memory, relative to healthy controls. This poor per-
formance was associated with poorer glycaemic control as 
indexed by HbA1c levels. DM2 patients also showed re-
duced hippocampal connectivity to surrounding bilateral 
brain regions including the frontal gyrus, fusiform gyrus and 
temporal gyrus. These studies suggest that functional net-
works intimately associated with memory are adversely af-
fected by DM2. These regions underpin memory processes 
such as face recognition [33] and word retrieval [34]; thus 
disruption to these networks may contribute to overall mem-
ory deficits. Further research should investigate whether 
there are observable functional differences between healthy 
individuals and those with DM2, allowing the tailoring of 
interventions to target the brain regions involved. 
Little research has looked at EEG frequencies (see Ap-
pendix 4) in DM2 (e.g. [35]), although a number of studies 
have been carried out in those with type 1 diabetes(DM1) 
[36]. Further work in the area should use EEG to investigate 
brain frequencies related to memory, such as the beta and 
gamma wave frequencies, particularly given that this activity 
has been found to be decreased in the temporal lobes of 
those with controlled DM1 [37]. Brismar et al. [37] sug-
gested that this decrease in activity may be linked to cogni-
tive decline in DM generally, so future research should ad-
dress this in those with DM2. Few studies have also looked 
at functional connectivity (the correlation of neuronal activ-
ity between separate distinct sites across the brain) in either 
DM1 or DM2. Such studies would enable the investigation 
of connectivity between brain regions associated with mem-
ory processing such as the frontal gyrus and hippocampus, 
consolidating research already done in the area using fMRI 
[29]. 
Some studies have indicated that patients with DM2 have 
a longer P300 latency [35, 38, 39], although others have 
found no differences compared to healthy controls [40]. Im-
portantly, strict glycaemic control has been shown to lead to 
improvements in P300 latency and potential memory en-
hancement [35, 39]. Cooray et al. [35] used EEG to investi-
gate the effects of glycaemic control on cognitive decline. 
They compared the behavioural cognitive performance and 
auditory ERPs ofi) DM2 patients on their regular treatment, 
ii) DM2 patients on an intensified glycaemic control regime 
(comprising of optimised drug treatment, frequent daily 
blood glucose monitoring and instructions on improving diet 
and exercise levels) and iii) healthy controls. Initially, indi-
viduals with DM2 performed significantly worse on tests of 
verbal fluency and visuospatial ability relative to healthy 
controls. Participants were presented with an auditory ERP 
task, whereby they pressed a response key in the left hand if 
they heard a low pitch tone or pressed a response key in the 
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right hand if they heard a high pitch tone. The authors ob-
served a lower N100 amplitude (indexing responses to un-
predictable auditory stimuli [41]) and longer P300 latency in 
DM2 patients. A lower EEG beta band resting activity 
(which is associated with alertness) was also observed, sug-
gesting that DM2 patients were less alert and attentive to the 
task. Those DM2 patients who then underwent intensified 
glycaemic control performed significantly better on the visu-
ospatial and semantic memory tasks at re-test. DM2 partici-
pants also demonstrated a significant increase in beta band 
connectivity, and the mean ERP amplitudes of the N100 and 
P300 components were significantly closer to healthy con-
trols (p< .001) than those patients on regular treatment. The 
improvements in cognitive ability and associated neurocog-
nitive ERPs show the importance of glycaemic monitoring 
and controlfor regulating cognitive performance in DM2. 
This study further highlights the importance of putting inter-
ventions in place to attenuate fluctuations in glycaemic con-
trol. However, the ERPs considered here are not related to 
more sensitive markers of memory retrieval (i.e. the recollec-
tion left-parietal and the familiarity old/new effect) [42]. 
These components have been used elsewhere to disentangle 
the memory impairments in normal ageing [43]. 
FUTURE DIRECTIONS AND CONCLUSIONS 
As seen above, neuroimaging can be used to explore the 
effects of physiological mechanisms associated with DM2 
on both brain structure and function, although evidence on 
functional deficits in DM2issparse. fMRI, EEG and ERP 
techniques have allowed the identification and investigation 
of specific memory impairments and deficits in other cogni-
tive domains, such as information processing and executive 
functions in DM2. A global effect on cognition could poten-
tially be identified through these methodologies to further 
our understanding of the effects of DM2.EEG frequency and 
connectivity studies have furthered our understanding of the 
neurocognitive mechanisms underpinning cognitive deficits 
inDM1; therefore future work in DM2 should follow a simi-
lar strategy to enhance current knowledge of deficits both 
memory and global cognition. 
Neuroimaging has had an impact on knowledge above 
and beyond that of behavioural research in the area by allow-
ing researchers to investigate the brain’s structural integrity 
and its influence on DM2 cognition. Both MRI (good spatial 
resolution) and ERPs (good temporal resolution) can be used 
to determine more precisely the neurocognitive mechanisms 
that underlie memory impairments. These techniques can 
potentially be used to determine whether deficits are pre-
dominantly explained by specific impairments in the encod-
ing, storage or retrieval of memories, or whether memory 
deficits are mediated by compromised structural integrity 
and functioning of the hippocampus. By using these neuroi-
maging techniques to their full potential, there is scope to 
develop targeted interventions that can help individuals with 
DM2 compensate for memory problems they may encounter. 
Identification of the precise mechanisms that underlie cogni-
tive complications in this condition may provide more spe-
cific avenues for intervention, including capitalisation on 
those aspects of memory functioning which remain intact. 
Importantly, these laboratory investigations will have impli-
cations for research on ‘real world’ memory and the cogni-
tive difficulties in the everyday lives for those with DM2, 
particularly when considering important tasks such as taking 
medications or remembering to attend medical appointments. 
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Appendix 1. Structural brain imaging has allowed re-
searchers to visualise structures and abnormalities (e.g. le-
sions, tumours etc) that may occur within the brain. Mag-
netic resonance imaging (MRI) is a prominent tool fre-
quently used in both structural and functional imaging. In 
MRI, signals from water molecule protons become differen-
tially aligned by the large magnet of an MRI scanner, subse-
quently allows the visualisation of the brain. It has been used 
to investigate changes in brain structure resulting from dia-
betes-related complications which may mediate the physio-
logical mechanisms mentioned above, as well as functional 
connectivity between the hippocampus and surrounding 
brain regions related to memory [29]. As such, many struc-
tural imaging studies have investigated the effects of DM2 
on the brain as a whole, as opposed to specific brain regions. 
Appendix 2. A proportion of neuroimaging research has 
focussed on trying to identify specific regions of atrophy 
within the brain that may explain the specific cognitive defi-
cits exhibited by individuals with DM2. In particular, atro-
phy in the hippocampus and temporal lobes have frequently 
been associated with impaired memory, even in ‘healthy’ 
older adults with impaired glucose tolerance [44]. The hip-
pocampus supports both recollection (remembering an item 
and the context it was last seen in) and familiarity (remem-
bering an item but not recalling details for when it was pre-
viously encountered), mechanisms considered integral to 
memory processing [45]. 
Appendix 3. Functional neuroimaging allows researchers 
to investigate regional brain activity during specific cogni-
tive tasks. This is commonly measured through imaging 
changes in the blood oxygen level dependent (BOLD) 
haemodynamic response in MRI, or via electrical activity 
through the scalp using EEG associated with direct activa-
tion of neural populations. 
Appendix 4. EEG is a neuroimaging method used to in-
vestigate cognitive function by measuring electrical brain 
activity through the scalp surface. This methodology offers 
excellent temporal resolution (milliseconds), allowing the 
measurement of brain frequencies and responses to particular 
events (known as event related potentials [ERPs]). This has 
enabled researchers to track cognitive processes such as 
unconscious versus conscious aspects of memory or states of 
alertness. One particular ERP component affected by DM2 is 
the P300. This component is a positive peak in the EEG 
waveform, detectable from approximately 300ms post stimu-
lus onset, often split into two separate subcomponents; the 
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P3a associated with executive function and orientation of 
attention and the P3b associated with memory updating and 
formation of memory representations [46]. 
ABBREVIATIONS 
AD = Alzheimer’s Disease 
BOLD response = Blood oxygen level dependent 
response 
DM2 = Type 2 Diabetes 
DTI = Diffusion Tensor Imaging 
EEG = Electroencephalogram 
ERP = Event-related Potential 
fMRI = Functional Magnetic Resonance 
Imaging 
HPA axis = Hypothalamic Pituitary Adrenal 
axis 
MRI = Magnetic Resonance Imaging 
WMH = White Matter Hypertensities 
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